SA
UTHR icon

Seneschal Advisors’s United Therapeutics UTHR Stock Holding History

Seneschal Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$593 Hold
1
– – ﹤0.01% 327
2025
Q4 		$488 Hold
1
– – ﹤0.01% 364
2025
Q3 		$420 Buy
+1
New +$336 ﹤0.01% 406

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Seneschal Advisors's UTHR Position: Q1 2026 in Review

Seneschal Advisors held its United Therapeutics (UTHR) position steady in Q1 2026 at 1 share worth $593. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Seneschal Advisors first reported a position in UTHR in Q3 2025 and has held it in 3 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Seneschal Advisors held 1 share of United Therapeutics worth $593 as of Q1 2026.
  • Seneschal Advisors left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up ﹤0.01% of Seneschal Advisors's portfolio in Q1 2026, its #327 holding.
  • Seneschal Advisors first reported a position in United Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Seneschal Advisors's 13F filing for Q1 2026, filed 8 May 2026.